drugset / Trial / NCT00881400

To Demonstrate the Relative Bioavailability of Cefzil 250 mg/5 ml Cefprozil Oral Suspension Fed Conditions

NCT00881400

Phase 1 Completed 24 enrolled Sandoz
RandomizedCrossoverOpen-labelTreatment

Summary

To demonstrate the relative bioavailability of Cefzil 250 mg/5 ml oral suspension fed conditions.

Timeline

Start
2004-06
Primary completion
2004-06
Completion
2004-06

Drugs

EvaluationDrugModalityDoseRoute
Subject CEFPROZIL ANHYDROUS, (E)- Small molecule 10 ml Oral

Indications

No indication recorded.